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Abstract. We retrospectively analyzed the background, clinical features, and treatment response of 50 cases of imported
loiasis who presented between 2000 and 2014 to the Hospital for Tropical Diseases (HTD), London, United Kingdom.
Of them, 29 were migrants from, and 21 were visitors to, countries where the disease is endemic. Clinical features differed
between these groups. Migrants experienced fewer Calabar swellings (odds ratio [OR] = 0.12), more eye worm (OR = 3.4),
more microfilaremia (OR = 3.5), lower filarial antibody levels, and lower eosinophil counts (P < 0.05 for all tests).
Among 46 patients who were started on treatment at HTD, 33 (72%) received diethylcarbamazine (DEC) monotherapy
as first-line treatment, and among 26 patients who were followed up after treatment, seven (27%) needed a second
course of treatment. There were 46 courses of treatment with DEC, and 20 (43%) of them had reactions. All patients
with microfilaremia > 3,000 microfilariae/mL and all those with an elevated C-reactive protein (CRP) (≥ 5 mg/L) before
treatment had reactions (P = 0.10 and P = 0.01, respectively). These data suggest that monotherapy with DEC may not
be the optimal treatment for patients with loiasis, particularly for those with a high microfilarial load.
INTRODUCTION
Loiasis is a systemic filarial infection caused by Loa loa.
It is also called “African eye worm” as adult worms can be
seen intermittently under the conjunctiva of infected people.
Another characteristic symptom is transient and migratory
edema, usually on the peripheries, known as Calabar swell-
ings. Loiasis is transmitted by adult female Chrysops flies
and its epidemiology is largely dependent on the distribution
of the fly: loiasis is confined to forest areas of central and
west Africa.1 More than 10 million people are estimated to
be infected,2 and in some areas loiasis is the most common
reason for visiting hospital.3
Loiasis is also seen as an imported infection among visitors
(travelers and expatriates) and migrants. One survey among
travel clinics showed loiasis constituted 25% of filarial infec-
tion seen in non-endemic countries.4 Previous reports have
described differences in the clinical features between visitors
to and migrants from endemic areas. Patients from non-
endemic countries are more likely to present with Calabar
swellings, eosinophilia, and positive filarial serology, but are
less likely to have microfilaremia and eye worm.5–8 These
differences are thought to result from differences in immuno-
logical responses to the worm,7,9,10 but it is unclear whether this
is because of host genetic differences or other factors such as
the duration of infection or the age at which infection occurred.
Traditionally, the mainstay treatment is chemotherapy with
diethylcarbamazine citrate (DEC) but significant reactions
during treatment commonly occur. Fatal encephalopathy is
known to be associated with the density of microfilariae.11,12
Corticosteroids and antihistamines are often used concomitantly
to reduce the severity of these reactions, although this is based
on expert opinion rather than shown by clinical studies.13,14
Loiasis, even as an imported disease, is relatively uncommon
outside west and central Africa, and most patients with imported
disease are treated at specialist centers. This study retrospec-
tively analyzed the demographics, clinical features, and treat-
ment response of 50 patients with loiasis seen at the Hospital for
Tropical Diseases (HTD), London, United Kingdom, between
2000 and 2014.
PATIENTS AND METHODS
Patients who had a working or final diagnosis of loiasis were
identified from two databases, which recorded all inpatients
and outpatients presenting to HTD between 2000 and 2014.
Cases were defined according to the following criteria. Proven
cases were those with confirmed microfilaremia of L. loa in
peripheral blood or those who had adult worms extracted,
usually from the eye. Probable cases were defined as those
with a clinical diagnosis of Calabar swellings and/or eye worm,
supported by treatment response and/or with positive filarial
serology, and who had been to west or central Africa but had
negative blood tests for microfilaremia. There were 30 proven
and 22 probable cases, but for two of the confirmed cases, the
case notes could not be traced. The following were extracted
from case notes and electronic records: demographic data,
travel history, presenting symptoms and signs, laboratory data,
details of treatment, and follow-up. Some records were missing
and the number of cases included was noted in the analysis.
To investigate different exposure effects on loiasis, we classi-
fied patients into two groups: Africans from endemic countries
(migrants) and all others (visitors).
Duration of stay in an endemic area was calculated as the
sum of the duration of any stay(s) in endemic countries. Maxi-
mum incubation period was calculated as the time between first
entry to an endemic country and the onset of symptoms or day
of diagnosis if asymptomatic.
The load of microfilaremia was assessed by filtration tech-
nique, usually using 20 mL peripheral blood collected in citrate
tubes around midday (“day bloods”) reflecting the periodicity
of the infection.
Filarial serology was assessed by an enzyme-linked immu-
nosorbent assay (ELISA) using a soluble extract of Brugia
pahangi adult worms. The results were expressed in banded
levels of optical density from 0 to 9, with a level of 1 or above
regarded as positive.
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Eosinophilia was defined as a peripheral blood eosinophil
count of more than 0.45 × 109/L. C-reactive protein (CRP)
was defined as positive when it was ≥ 5 mg/L.
Reactions to treatment were defined as new symptoms or
worsening of pruritus during and within 7 days after the start
of chemotherapy.
STATA/IC 13.1 (StataCorp LP, College Station, TX) was
used to analyze the data with Mann–Whitney’s U tests and
two-sided t tests for analyzing quantitative data as appropriate.
The first quartile (Q1) and third quartile (Q3) are shown in
square brackets [Q1–Q3] and 95% confidence intervals (CIs)
are shown in parentheses. For categorical data, χ2 tests or
Fisher’s exact tests with two-sided uncorrected P value were
used as appropriate.
RESULTS
Background of patients. Migrants and visitors had different
characteristics (Table 1). The median age at first symptoms
among migrants was 11 years younger (P = 0.003). Median dura-
tion of stay in endemic areas among migrants (270 months) was
longer than that among visitors (6 months). Similarly, the maxi-
mum incubation period was longer among migrants (294 months
in median) than that among visitors (10.5 months, P < 0.001).
The most common countries of acquisition among migrants
were Nigeria (16/29, 55%) and Cameroon (9/29, 31%), whereas
those among visitors were Cameroon (6/20, 30%), Central
African Republic (4/20, 20%), and Gabon (3/20, 15%). Infor-
mation from one visitor was not available.
Symptoms and signs. Migrants experienced fewer Calabar
swellings (odds ratio [OR] = 0.12, 95% CI = 0.03–0.47,
P = 0.002) and more eye worm (OR = 3.4, 95% CI = 1.0–11.4,
P = 0.049). Other eye symptoms, such as redness, swelling of the
conjunctiva, and a sensation of worms crawling under the eyelids,
were relatively common (42% of all patients). The frequency
of other symptoms was not different between the groups and
physical examination was usually unremarkable (Table 2).
Calabar swellings were commonly reported on the extremi-
ties: hand or wrist (19/30, 63%), forearm (21/30, 70%), upper
arm (3/30, 10%), leg (10/30, 33%), and feet (7/30, 23%). Other
sites included eyelids (5/30, 17%), lips, postauricular area, neck,
and chest. Of the patients, 37% reported pain and 47% had
itchiness at the sites of swellings, but only 10% described both.
Duration of any one swelling ranged from several hours to
about 2 weeks.
Eight patients had both Calabar swellings and eye worm.
Five of these (63%) had swellings 6–128 months earlier. Three
(38%) had both at almost the same time, and there were no
cases where eye worm preceded Calabar swellings.
Laboratory findings before treatment. Total eosinophil counts
were lower among migrants (P = 0.004), although the propor-
tion of patients with eosinophilia was high in both groups
(72% of migrants and 86% of visitors) (Table 3). Microfilariae
were seen more frequently among migrants (OR = 3.5, 95%
CI = 1.0–11.7, P = 0.04). The number of microfilariae in micro-
filaremic patients was not different (P = 0.63), although the
maximum microfilarial load in migrants was higher than that
in visitors (301,000 and 5,600 microfilariae/mL [mf/mL],
respectively). Filarial serology was positive less frequently
(OR = 0.27, 95% CI = 0.07–0.98, P = 0.05) and with lower
optical density among migrants (P = 0.004).
“Night bloods” for microfilaremia, taken around midnight,
were examined in seven of 28 cases who had microfilaremia
to rule out the possibility of coinfection with Wuchereria
bancrofti. None of them were found to be coinfected.
Treatment options. Information about treatment was avail-
able for 48 cases. Of them, 46 started treatment of loiasis at
HTD. The treatment of choice was DEC (33/46, 72%) but,
because of problems with consistent supply of this drug and
dependent on the microfilarial load, other anthelmintics were
used: ivermectin alone (4/46, 9%), albendazole alone (4/46,
9%), ivermectin followed by DEC (3/46, 7%), albendazole
plus ivermectin (1/46, 2%), and albendazole followed by DEC
(1/46, 2%). Decisions in all of the albendazole plus ivermectin
group, 75% of the albendazole group and half of the ivermec-
tin group could be attributed to the limited supply of DEC
at that time. A combination of ivermectin or albendazole
followed by DEC was chosen on clinical grounds for some
patients with higher microfilarial loads.
The dose of DEC was 600 mg/day for 21 days for all
patients except one who was given 450 mg/day adjusted to his
body weight. DEC was started from a low dose (50 mg/day)
and was gradually increased to the full dose over 2–4 days.
The ivermectin dose was based on body weight: approxi-
mately 0.2 mg/kg/day ranging from 12 to 20 mg/day as a single
dose. The albendazole dose was 400 mg/day for 21 days for
all patients except one who was given 800 mg/day. In all
patients with microfilaremia except one, DEC was started as
an inpatient, while other drugs were sometimes prescribed on
an outpatient basis.
Reaction. In total and allowing for retreatments, there
were 71 courses of treatment. Reactions were reported dur-
ing 21 (30%). The only marked reaction was severe pruritus,
which necessitated an interruption of treatment with DEC
TABLE 1
Characteristics of patients stratified by migrants and visitors
Migrants Visitors P value*
Number of patients 29 21 –
Age at first symptom (in years) Median: 25.0 [21.0–31.0] (N = 29) Median: 36.0 [27.0–51.0] (N = 21) 0.003
Sex Male: 14 (48%) Male: 16 (76%) –
Female: 15 (52%) Female: 5 (24%)
Duration of stay in endemic countries (months) Median: 270 [201–310] Median: 6 [3–30] < 0.001
Minimum: 36 Minimum: 1.25
Maximum: 636 (N = 28) Maximum: 120 (N = 13)
Maximum incubation period (months) Median: 294 [240–340] Median: 10.5 [8–48] < 0.001
Minimum: 48 Minimum: 4
Maximum: 642 (N = 20) Maximum: 144 (N = 10)
– = not applicable.
*Mann–Whitney’s U tests are used.
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in one patient. The other 20 reports were mild and tolerable.
There were 20 reactions (43%) among patients treated with
DEC and one (7%) among patients treated with ivermectin.
There were no reports of reactions among patients treated with
albendazole (N = 8) or albendazole plus ivermectin (N = 4).
There could have been reporting bias depending on whether
patients were hospitalized or not, although most treatment was
started during hospitalization: DEC (33/46), ivermectin (4/14),
albendazole (5/8), and albendazole plus ivermectin (1/4).
Next, we assessed factors that were associated with reaction
in patients treated with DEC as first treatment. All patients
with microfilaremia > 3,000 mf/mL had reactions (100% ver-
sus 46%, P = 0.10). All patients with raised CRP (≥ 5.0 mg/L)
before treatment had reactions (100% versus 35%, P = 0.01).
Planned preventive use of corticosteroid was not associated
with reaction; 60% of users and 44% of nonusers experienced
reaction (P = 0.48).
Treatment outcome. A total of 36 patients (75%) received
one treatment course, 10 patients (21%) received two, one
patient (2%) received four, and one patient (2%) received five
courses. Sixty courses of treatment from 41 patients were
followed up after completion of treatment for a median period of
95 [24–291] days. The percentage of patients who underwent
retreatment after the first course was 27% (7/26) for DEC, 60%
(3/5) for ivermectin, 67% (2/3) for albendazole, 50% (1/2)
for ivermectin plus albendazole, and 0% (0/2) for ivermectin
followed by DEC. Seven patients received two courses of a
DEC-containing regimen. None received DEC more than twice.
The reasons for the second treatment of the DEC-containing
regimen were recurrent Calabar swellings (N = 4), recurrent eye
worm (N = 1), persistent microfilaremia (N = 1), and persistent
eosinophilia (N = 1). Eight patients did not receive DEC treat-
ment. Of these, only three had confirmed clinical improvement
after therapy, and the other five were lost to follow-up.
DISCUSSION
Characteristics of symptoms. Classically, Calabar swellings
are said to be non-tender.3 However, more than one-third of
the patients with Calabar swellings complained of pain or itch.
This is consistent with a previous report from endemic areas.15
Although Calabar swellings typically appear on extremities,3,13
some patients experienced swellings on other parts of the
body: swellings on the eyelid were seen more frequently than
that on the upper arms in this series.
“Other eye symptoms” were more frequently seen than eye
worm. This could be due to unnoticed eye worm because con-
junctivitis has been reported after the observation of eyeworm.16
Differences between migrants and visitors. This study con-
firms previous findings on differences between migrants and
visitors; Calabar swellings and positive filarial serology were
reported less frequently whereas eye worm and microfilaremia
were reported more frequently among migrants; eosinophilia
was commonly found among both groups (Table 4).
TABLE 2
Symptoms and signs among migrants and visitors and OR for migrants on appearance of symptoms and signs
Migrants (N = 29) Visitors (N = 21) OR (95% CI) P value*
Symptoms
Calabar swellings 12 (41%) 18 (86%) 0.12 (0.03, 0.47) 0.002
Eye worm 15 (52%) 5 (24%) 3.4 (1.0, 11.4) 0.049
Other eye symptoms 14 (48%) 7 (33%) 1.9 (0.59, 5.8) 0.30
Fever 5 (17%) 3 (14%) 1.3 (0.29, 5.4) 0.78
Arthralgia 3 (10%) 5 (24%) 0.37 (0.09, 1.6) 0.20
Myalgia 1 (3%) 3 (14%) 0.21 (0, 1.7) 0.17
Pruritus 9 (31%) 2 (10%) 4.3 (0.90, –) 0.07
Urticaria/rash 3 (10%) 4 (19%) 0.49 (0.11, 2.2) 0.39
Asymptomatic 1 (3%) 0 (0%) – 0.39
Physical signs
Calabar swellings 8 (28%) 9 (43%) 0.51 (0.16, 1.6) 0.27
Eye worm 9 (31%) 4 (19%) 1.9 (0.52, 6.9) 0.35
Fever 3 (10%) 1 (5%) 2.3 (0.30, –) 0.48
Lymphadenopathy 1 (4%) 0 (0%) – 0.39
CI = confidence interval; OR = odds ratio; – = not applicable.
*χ2 tests are used.
TABLE 3
Characteristic laboratory findings among migrants and visitors and OR for migrants on positive findings
Migrants Visitors OR (95% CI) P value
Eosinophilia 21/29 (72%) 18/21 (86%) 0.4 (0.1, 1.8) 0.26*
Geometric mean of eosinophil counts (95% CI) (×109/L) 0.71 (0.50–1.00) (N = 27) 2.04 (0.97–4.28) (N = 18) – 0.004†
Microfilaremia 20/29 (69%) 7/18 (39%) 3.5 (1.0, 11.7) 0.04*
Microfilarial load in microfilaremic
patients (mf/mL)
Median 759 Median 1,172 – 0.63‡
IQR [167–6,265] IQR [50–2,000]
Maximum 301,000 Maximum 5,600
(N = 20) (N = 6)
Positive filarial serology 14/27 (52%) 16/20 (80%) 0.3 (0.1, 1.0) 0.05*
Median serology levels in seropositive patients [IQR] 2.0 [2.0–4.0] (N = 14) 5.0 [4.0–7.0] (N = 14) – 0.004‡
CI = confidence interval; IQR = interquartile range; mf = microfilariae; OR = odds ratio; – = not applicable.
*χ2 tests were used.
† t test was used.
‡Mann–Whitney’s U tests were used.
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Treatment outcome. Although the definition of cure and
duration of follow-up varied between previous reports, treatment
failure was reported among 10–65% of patients treated with
DEC. This variation in failure rate may be explained by differ-
ences in the microfilarial burden between patients in each
study. An alternative explanation may be different length of
follow-up and/or criteria for re-treatment between studies.
Although these factors make it difficult to assess the efficacy
of DEC, it would appear that the rate of treatment failure
may be around one in three if DEC is used alone. However,
neither ivermectin nor albendazole can provide a cure for the
disease without DEC as DEC is the only drug that kills the
adult worm.3 A combination of DEC given after ivermectin or
albendazole may be the most appropriate strategy, depending
to some extent on the microfilarial load with albendazole
used as first-line treatment in those with very high burdens.
Reported rates of reaction are variable, ranging from 0%6
to > 50%.14,17 This might be due to the variable criteria for
defining a reaction. The evidence in favor of corticosteroid
use against reaction is unclear. In this series, preventive use of
corticosteroids did not have an impact on the rate of reaction,
though this might be because high-risk patients with high
microfilaremia were more likely to receive corticosteroids.
A previous series reported a very low incidence of reactions
even though none of those patients received corticosteroids.6
Preventive use of antihistamine drugs has been suggested to
reduce the severity but not the frequency of adverse reaction.3
Risk factor for reactions. A high microfilarial load is a known
risk factor for encephalopathy after treatment, although there
is a report of a patient with a level as low as 700 mf/mL who
became encephalopathic.20 Rapid clearance of microfilaremia is
supposedly responsible for the development of encephalopathy,
but only a few studies have examined pretreatment micro-
filarial density in patients with encephalopathy.21,22 It has been
suggested that a reduction of more than 30,000 mf/mL in
3 days may increase the risk of encephalopathy occurring.23
This study suggests that raised CRP before treatment may
also be a predictive risk factor for mild reactions. An increase
in CRP after treatment has been reported among those who
have severe adverse events after ivermectin,24 and is assumed
to be related to the absolute number of microfilariae killed by
treatment.23 This could not be confirmed in this study because
few of the patients were examined in the first few days of
treatment without corticosteroid.
In summary, the success rate of DEC as first-line treatment
of loiasis is unsatisfactory. Other treatment regimens including
combinations of drugs should be investigated, particularly
among patients with a high microfilarial load.
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